Johnson & Johnson profit beat fueled by strength in pharma business
July 17, 2018 at 09:13 AM EDT
Johnson & Johnson topped analysts' estimates for quarterly profit and revenue on Tuesday, as strong demand for cancer drugs Zytiga and Darzalex more than made up for declining sales of blockbuster treatment Remicade.